Liposome-assisted combination chemotherapy improves the anti-proliferation and anti-angiogenesis response of cisplatin in breast cancer; experimental and computational study.
Nasim Valinezhadi, Gholamreza Dehghan, Mohammad Yaghoubzad-Maleki, Maryam Mohammadi, Ali Akbar Alizadeh, Hamed Hamishehkar
{"title":"Liposome-assisted combination chemotherapy improves the anti-proliferation and anti-angiogenesis response of cisplatin in breast cancer; experimental and computational study.","authors":"Nasim Valinezhadi, Gholamreza Dehghan, Mohammad Yaghoubzad-Maleki, Maryam Mohammadi, Ali Akbar Alizadeh, Hamed Hamishehkar","doi":"10.1080/1120009X.2025.2484078","DOIUrl":null,"url":null,"abstract":"<p><p><b>Abstract</b>Combination chemotherapy using liposomes offers a promising approach to overcome chemotherapy resistance and minimize side effects in breast cancer treatment. This study explores the synergistic effects of all-trans-retinoic acid (ATRA) and cinnamaldehyde (CA) combined with cisplatin (CPT) in MDA-MB-231 breast cancer cells. The liposomal formulation, CPT_ATRA_CA, significantly reduced cell proliferation to 25.9 ± 2.8% compared to controls and effectively inhibited angiogenesis. Additionally, it induced apoptosis, as demonstrated by flow cytometry, DAPI staining, and an elevated Bax/Bcl-2 gene expression ratio. Computational analysis via molecular docking and molecular dynamics simulation revealed that ATRA exhibited the highest binding affinity for angiogenin (ANG) with a binding energy of -106.072 kcal/mol. Experimental results, corroborated by computational data, highlight the potent anti-tumor effects of this drug trio. These findings suggest that liposomal delivery of ATRA, CA, and CPT could enhance therapeutic outcomes in breast cancer by targeting multiple pathways synergistically.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-18"},"PeriodicalIF":1.9000,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1120009X.2025.2484078","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
AbstractCombination chemotherapy using liposomes offers a promising approach to overcome chemotherapy resistance and minimize side effects in breast cancer treatment. This study explores the synergistic effects of all-trans-retinoic acid (ATRA) and cinnamaldehyde (CA) combined with cisplatin (CPT) in MDA-MB-231 breast cancer cells. The liposomal formulation, CPT_ATRA_CA, significantly reduced cell proliferation to 25.9 ± 2.8% compared to controls and effectively inhibited angiogenesis. Additionally, it induced apoptosis, as demonstrated by flow cytometry, DAPI staining, and an elevated Bax/Bcl-2 gene expression ratio. Computational analysis via molecular docking and molecular dynamics simulation revealed that ATRA exhibited the highest binding affinity for angiogenin (ANG) with a binding energy of -106.072 kcal/mol. Experimental results, corroborated by computational data, highlight the potent anti-tumor effects of this drug trio. These findings suggest that liposomal delivery of ATRA, CA, and CPT could enhance therapeutic outcomes in breast cancer by targeting multiple pathways synergistically.
期刊介绍：
The Journal of Chemotherapy is an international multidisciplinary journal committed to the rapid publication of high quality, peer-reviewed, original research on all aspects of antimicrobial and antitumor chemotherapy.
The Journal publishes original experimental and clinical research articles, state-of-the-art reviews, brief communications and letters on all aspects of chemotherapy, providing coverage of the pathogenesis, diagnosis, treatment, and control of infection, as well as the use of anticancer and immunomodulating drugs.
Specific areas of focus include, but are not limited to:
· Antibacterial, antiviral, antifungal, antiparasitic, and antiprotozoal agents;
· Anticancer classical and targeted chemotherapeutic agents, biological agents, hormonal drugs, immunomodulatory drugs, cell therapy and gene therapy;
· Pharmacokinetic and pharmacodynamic properties of antimicrobial and anticancer agents;
· The efficacy, safety and toxicology profiles of antimicrobial and anticancer drugs;
· Drug interactions in single or combined applications;
· Drug resistance to antimicrobial and anticancer drugs;
· Research and development of novel antimicrobial and anticancer drugs, including preclinical, translational and clinical research;
· Biomarkers of sensitivity and/or resistance for antimicrobial and anticancer drugs;
· Pharmacogenetics and pharmacogenomics;
· Precision medicine in infectious disease therapy and in cancer therapy;
· Pharmacoeconomics of antimicrobial and anticancer therapies and the implications to patients, health services, and the pharmaceutical industry.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
